Management of noninvasive bladder cancers

John B Eifler, Kristen R Scarpato, Peter E Clark

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

PURPOSE OF REVIEW: To summarize clinical management of nonmuscle-invasive bladder cancer (NMIBC) and discuss recent advances in the field.

RECENT FINDINGS: NMIBC remains a common and expensive clinical entity. Prevention, early detection, and risk-adapted treatment are the mainstays of clinical management, all of which may improve as a result of recent research. Photodynamic diagnosis has demonstrated improved detection of nascent disease, and specific clinical scenarios have been identified in which photodynamic diagnosis may improve clinical outcomes. New intravesical chemotherapeutic and immunotherapeutic agents challenge our current paradigm for intermediate/high-risk NMIBC and may delay need for cystectomy after bacillus Calmette-Guerin failure. Progress in risk stratification increasingly permits individualized management regimens for NMIBC.

SUMMARY: NMIBC includes many heterogeneous disease states with a variety of clinical behaviors that may evolve over time. Improved detection and risk stratification promise assignment of the optimal treatment option for an individual patient at a given time.

Original languageEnglish
JournalCurrent Opinion in Oncology
Volume27
Issue number3
Pages (from-to)185-90
ISSN1040-8746
DOIs
Publication statusPublished - 2015
Externally publishedYes

Keywords

  • Administration, Intravesical
  • Antineoplastic Agents
  • Cystectomy
  • Doxorubicin
  • Early Detection of Cancer
  • Humans
  • Neoplasm Recurrence, Local
  • Risk Assessment
  • Risk Reduction Behavior
  • United States
  • Urinary Bladder Neoplasms
  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'Management of noninvasive bladder cancers'. Together they form a unique fingerprint.

  • Cite this